Laura Téblick

Mrs. Laura Téblick

Centre for the Evaluation of Vaccination (CEV)
+2
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Laura TéblickLaura Téblick
Laura Téblick
SKSeverien Van Keer
Severien Van Keer
ASAnnemie De Smet
Annemie De Smet
PDPierre Van Damme
Pierre Van Damme
MLMichelle Laeremans
Michelle Laeremans
AVAlex Vorsters
Alex Vorsters
The potential of first-void (FV) urine as a non-invasive liquid biopsy for detection of human papillomavirus (HPV) DNA and other biomarkers has been increasingly recognized over the past decade. In this study, we investigated whether the volume of this initial urine stream has an impact on the analytical performance of biomarkers. In parallel, we evaluated different DNA extraction protocols and introduced an internal control in the urine preservative. Twenty-five women, diagnosed with high-risk HPV, provided three home-collected FV urine samples using three FV urine collection devices (Colli-Pee) with collector tubes that differ in volume (4, 10, 20 mL). Each collector tube was prefilled with Urine Conservation Medium spiked with phocine herpesvirus 1 (PhHV-1) DNA as internal control. Five different DNA extraction protocols were compared, followed by PCR for GAPDH and PhHV-1 (qPCR), HPV DNA, and HBB (HPV-Risk Assay), and ACTB (methylation-specific qPCR). Results showed limited effects of collection volume on human and HPV DNA endpoints. In contrast, significant variations in yield for human endpoints were observed for different DNA extraction methods (p < 0.05). Additionally, the potential of PhHV-1 as internal control to monitor FV urine collection, storage, and processing was demonstrated.

18 September 2019 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
JPJade Pattyn
Jade Pattyn
SKSeverien Van Keer
Severien Van Keer
Laura TéblickLaura Téblick
Laura Téblick
PDPierre Van Damme
Pierre Van Damme
AVAlex Vorsters
Alex Vorsters
(2019). HPV DNA detection in urine samples of women: ‘an efficacious and accurate alternative to cervical samples?’. Expert Review of Anti-infective Therapy. Ahead of Print.

14 August 2023 in Preventive Medicine Reports
Verified
Journal Article
Open access
DWDur-E-Nayab Waheed
Dur-E-Nayab Waheed
FBF. Ricardo Burdier
F. Ricardo Burdier
CECarina Eklund
Carina Eklund
IBIacopo Baussano
Iacopo Baussano
FMFilipe Colaço Mariz
Filipe Colaço Mariz
AVAlex Vorsters
Alex Vorsters
• Clinical trial subjects followed up for up to 10 years after receiving one dose HPV vaccine show stable antibody levels. • One dose vaccine efficacy against vaccine-type incidence persistent infection in India and Costa Rica cohorts is > 80%. • Further study is needed for one-dose HPV vaccination in HIV + individuals, but it shouldn’t delay general adoption. • HPV vaccine immune response plateaus at 24 months. Studies with 24 + months follow-up are needed for accurate comparison. • Anchored International Standards for 9 HPV vaccine genotypes will facilitate immunogenicity reporting and assay optimisation.

5 August 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JPJade Pattyn
Jade Pattyn
SKSeverien Van Keer
Severien Van Keer
Laura TéblickLaura Téblick
Laura Téblick
PDPierre Van Damme
Pierre Van Damme
AVAlex Vorsters
Alex Vorsters
The potential of first-void (FV) urine as a non-invasive method to monitor human papillomavirus (HPV) vaccination has been reported, mainly focusing on urine as a sample to assess HPV DNA. Besides HPV DNA, vaccine-induced HPV antibodies originating from cervicovaginal secretions were recently shown to be detectable in FV urine as well. This presents a novel opportunity for non-invasive sampling to monitor HPV antibody status in women participating in large epidemiological studies and HPV vaccine trials. The simultaneous assessment of both HPV infection and immunogenicity on a non-invasive, readily obtained sample is particularly attractive.

8 April 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
JPJade Pattyn
Jade Pattyn
GPGitika Panicker
Gitika Panicker
MWMartina Willhauck‐Fleckenstein
Martina Willhauck‐Fleckenstein
SKSeverien Van Keer
Severien Van Keer
Laura TéblickLaura Téblick
Laura Téblick
AVAlex Vorsters
Alex Vorsters
Vaccine‐induced human papillomavirus (HPV) antibodies originating from cervicovaginal secretions were recently shown to be detectable in first‐void (FV) urine. This presents a novel opportunity for noninvasive sampling to monitor HPV antibody status in women participating in large epidemiological studies and HPV vaccine trials. With a view towards method optimization, this study compared the measurement of HPV antibodies in FV urine using a multiplex L1/L2 virus‐like particles (VLP)‐based ELISA (M4ELISA) with previously reported results using a glutathione S‐transferase (GST)‐L1‐based immunoassay (GST‐L1‐MIA). We tested 53 paired FV urine and serum samples from 19‐ to 26‐year‐old healthy women, unvaccinated (n = 17) or vaccinated with either the bivalent or quadrivalent HPV‐vaccine during adolescence (n = 36). HPV6/11/16/18 antibodies were measured using M4ELISA and compared with GST‐L1‐MIA results. Inter‐assay and inter‐specimen correlations were examined using the Spearman's rank test (rs). As expected, lower HPV antibody concentrations were found in FV urine than in serum. Vaccinated women had significantly higher HPV6/11/16/18 antibody levels in both FV urine and serum compared with those unvaccinated (M4ELISA; FV urine P = .0003; serum P ≤ .0001). HPV antibody levels in FV urine and serum showed a significant positive correlation (M4ELISA anti‐HPV6/11/16/18, rs = 0.85/0.86/0.91/0.79, P ≤ .001). Despite assay differences, there was moderate to good correlation between M4ELISA and GST‐L1‐MIA (FV urine anti‐HPV6/11/16/18, rs = 0.86/0.83/0.89/0.53, P ≤ .0001; serum anti‐HPV6/11/16/18, rs = 0.93/0.89/0.94/0.75, P ≤ .0001). FV urine HPV antibody detection is comparable with both assays, further supporting this noninvasive sampling method as a possible option for HPV vaccine assessment. Approaches to improve the sensitivity and larger studies are warranted to determine the feasibility of FV urine for vaccine‐induced HPV antibody detection.

21 February 2025 in Journal of Medical Virology
Verified
Journal Article
Closed access
SKSeverien Van Keer
Severien Van Keer
Laura TéblickLaura Téblick
Laura Téblick
GDGilbert Donders
Gilbert Donders
SWSteven Weyers
Steven Weyers
JDJean Doyen
Jean Doyen
AVAlex Vorsters
Alex Vorsters